Evidence map›Paper›PMID 28277490›Full record

Trial reportJournal of perinatology : official journal of the California Perinatal Association2017

Erythropoietin monotherapy in perinatal asphyxia with moderate to severe encephalopathy: a randomized placebo-controlled trial.

R R Malla, R Asimi, M A Teli, F Shaheen, M A Bhat

Registry-linked trialAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Journal of perinatology : official journal of the California Perinatal Association, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03882060 (The Effect of Recombinant Human Erythropoietin on the Postoperative Neurologic Outcome in Pediatric Moyamoya Disease Patients - A Double Blind Randomized Controlled Trial), which is not on this map. Cited by 44 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 9 pooled it
12.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03882060 naunknown statusnot on this mapstarted 2019, after this paper: background citation

The Effect of Recombinant Human Erythropoietin on the Postoperative Neurologic Outcome in Pediatric Moyamoya Disease Patients - A Double Blind Randomized Controlled Trial

TypeinterventionalSponsorSeoul National University HospitalRan2019 to 2023Enrolled60ConditionsMoyamoya Disease, Pediatrics, Cerebrovascular DisordersArmserythropoietin, Normal saline
3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 9 syntheses or guidelines pooled it, 80 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Article
  13. Comparison of the prognosis of asphyxiated infants receiving hypothermia therapy with those receiving erythropoietin: a prospective cohort study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

R R MallaDepartment of Paediatrics, Sheri Kashmir Institute of Medical Sciences, Srinagar, India.
R AsimiDepartment of Neurology, Sheri Kashmir Institute of Medical Sciences, Srinagar, India.
M A TeliDepartment of Paediatrics, Sheri Kashmir Institute of Medical Sciences, Srinagar, India.
F ShaheenDepartment of Radiodiagnosis and Imaging, Sheri Kashmir Institute of Medical Sciences, Srinagar, India.
M A BhatDepartment of Paediatrics, Sheri Kashmir Institute of Medical Sciences, Srinagar, India.
Sher-i-Kashmir Institute of Medical Sciences · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveErythropoietin (EPO) is neuroprotective after asphyxia in animal studies. The efficacy and safety of EPO monotherapy in term neonates with hypoxic ischemic encephalopathy (HIE) is uncertain. STUDY

designHundred term neonates with moderate or severe HIE were randomized by random permuted block algorithm to receive either EPO 500 U kg

resultsDeath or moderate or severe disability occurred in 40% of neonates in the treatment group vs 70% in the placebo group (risk ratio, 0.57; 95% confidence interval (CI) 0.38 to 0.85; P=0.003). Death occurred in 16% of patients in both the groups (risk ratio, 1.0; 95% CI 0.33 to 2.9; P=0.61). The risk of cerebral palsy was lower among survivors in the treatment group (risk ratio, 0.52; 95% CI 0.25 to 1.03; P=0.04) and lesser number of babies were on anticonvulsants at assessment (risk ratio, 0.47; 95% CI 0.20 to 1.01; P=0.03). Neonatal brain magnetic resonance imaging showed more abnormalities in the placebo group (relative risk, 0.66; 95% CI 0.42 to 1.03; P=0.04)). Improvement in other neurological outcomes was not significant.

conclusionEPO monotherapy reduces the risk of death or disability in term neonates with moderate or severe encephalopathy.

Indexed as

Asphyxia NeonatorumBrainCerebral PalsyDouble-Blind MethodErythropoietinFemaleHumansHypoxia-Ischemia, BrainIndiaInfantInfant, NewbornLongitudinal StudiesMagnetic Resonance ImagingMaleProspective StudiesSeverity of Illness IndexErythropoietin

Identifiers

PMID28277490
OpenAlexW2592563207

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.